Rapport Therapeutics (RAPP) Liabilities and Shareholders Equity (2023 - 2026)

Rapport Therapeutics (RAPP) has reported Liabilities and Shareholders Equity for 4 consecutive years, with $497.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 64.74% year-over-year to $497.6 million; the TTM figure through Mar 2026 stood at $1.8 billion (up 41.46% YoY), while the FY2025 annual figure was $512.4 million, up 62.71% from the prior year.
• Liabilities and Shareholders Equity fell to $497.6 million in Q1 2026 per RAPP's latest filing, from $512.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $535.3 million in Q3 2025 and bottomed at $155.4 million in Q4 2023.
• Historically, Liabilities and Shareholders Equity has averaged $364.5 million across 4 years, with a median of $331.1 million in 2024.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity soared 102.63% — and 2025, when it declined 17.51%.
• Rapport Therapeutics' Liabilities and Shareholders Equity stood at $155.4 million in 2023, then soared by 102.63% to $314.9 million in 2024, then surged by 62.71% to $512.4 million in 2025, then retreated by 2.89% to $497.6 million in 2026.
• Business Quant data shows RAPP's Liabilities and Shareholders Equity at $497.6 million in Q1 2026, $512.4 million in Q4 2025, and $535.3 million in Q3 2025.